tcv-309 and Pulmonary-Edema

The effect of TCV-309, a newly developed platelet activating factor (PAF) antagonist, on the wet/dry weight ratio of the lung (index of pulmonary edema) and the pulmonary surface activity (index of pulmonary compliance) was evaluated in comparison with that of CV-3988 (PAF-antagonist). Administration of TCV-309 (1 mg/kg) or CV-3988 (10 mg/kg) significantly reduced the wet/dry weight ratio which was increased by endotoxin administration (3 mg/kg). It also augmented the pulmonary surface activity. Administration of either TCV-309 or CV-3988 alleviated the histologic lesions caused by endotoxic shock. These results suggest that lung injury during endotoxic shock can be controlled by TCV-309 as by CV-3988.

Topics: Animals; Dogs; Escherichia coli; Isoquinolines; Lipopolysaccharides; Lung; Phospholipid Ethers; Platelet Activating Factor; Platelet Aggregation Inhibitors; Pulmonary Edema; Pulmonary Surfactants; Pyridinium Compounds; Shock, Septic; Tetrahydroisoquinolines